VAUGHAN, Ontario–(BUSINESS WIRE)–Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from a Phase 2 study evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing pain following photorefractive keratectomy (PRK) surgery. “What stands out from this study is the consistency of the findings,” said Yehia Hashad, MD, executive vice president, R&D and

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.